NY-ESO-1

NY-ESO-1

NY-ESO-1 詳細

Molecule Name
Cancer/testis antigen 1
分子の別称
NY-ESO-1
Drug Development Progress
治験薬の数25
市販薬剤の数0
研究&開発段階Phase 3 Clinical
ターゲットの別称
CTAG1A more,Autoimmunogenic cancer/testis antigen NY-ESO-1,LAGE2A,CTAG1,CTAG1A,CTAG1B,Cancer/Testis Antigen 1B,Cancer/Testis Antigen 6.1,L Antigen Family Member 2,Cancer/Testis Antigen 1,LAGE-2,LAGE2B,CT6.1,CTAG,ESO1,Cancer Antigen 3,NY-ESO-1,LAGE2,New York Esophageal Squamous Cell Carcinoma 1
バックグランド
Cluster of Differentiation 3 (CD3) is a pivotal multimeric T cell co-receptor complex essential for adaptive immune responses. Composed of epsilon (ε), gamma (γ), delta (δ), and zeta (ζ) polypeptide chains forming three distinct dimers (εγ, εδ, ζζ), CD3 non-covalently associates with the T-cell receptor (TCR) to establish the critical TCR/CD3 receptor complex on T cell surfaces. Structurally, CD3 proteins belong to the immunoglobulin superfamily, featuring a transmembrane domain, an N-terminal extracellular region with immunoglobulin-like domains, and cytoplasmic tails embedded with immunoreceptor tyrosine-based activation motifs (ITAMs). These ITAMs are fundamental for initiating signal transduction upon T cell receptor engagement, thereby activating both CD4+ T helper and CD8+ cytotoxic T cells. As a defining marker of the T cell lineage, CD3's central role in T cell activation makes its modulation, via stimulating or blocking antibodies, a promising therapeutic avenue for conditions like organ transplant rejection and autoimmune diseases.

NY-ESO-1 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
mipetresgene autoleucelTBI-1301Phase 3 ClinicalTakara Bio Inc
Esophageal Neoplasms; Liver Neoplasms; Lung Neoplasms; Melanoma; Ovarian Neoplasms; Sarcoma, Synovial; Solid tumours; Urinary Bladder Neoplasms
詳細
TCR Affinity Enhancing Specific T cell TherapyTAEST-16001Phase 2 ClinicalGuangzhou Institute Of Respiratory Health, Guangzhou Xiangxue Pharmaceutical Co Ltd
Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Liver Neoplasms; Osteosarcoma; Ovarian Neoplasms; Sarcoma; Solid tumours; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms
詳細
Cancer vaccine NY-ESO-1 (Ludwig Institute/Peking University/Jewim Pharmaceutical)Phase 2 ClinicalLudwig Institute For Cancer Research
Liver Neoplasms; Melanoma
詳細
Anti-NY-ESO-1 TCR-T cell theray (Shenzhen BinDeBio)Phase 2 ClinicalShenzhen Bindebio Ltd
Carcinoma, Hepatocellular; Esophageal Neoplasms; Glioma; Stomach Neoplasms
詳細
Autologous anti-NY-ESO1 T-cell receptor gene-engineered peripheral blood lymphocytes (Roswell)CD8-TCR-T cells; NY-ESO-1/CD8/HL AA2.1-19305dp-TCR-T cellsPhase 2 ClinicalRoswell Park Cancer Institute
Neoplasms
詳細
VTP-600VTP-600Phase 2 ClinicalBarinthus Biotherapeutics PLC, Ludwig Institute For Cancer Research
Carcinoma, Non-Small-Cell Lung
詳細
NY-ESO-1TCR/dnTGFBRII Engineered T Cells therapy (The University Of Chicago)NY-ESO-1 TCR/ dnTGFβRIIPhase 2 ClinicalThe University Of Chicago
Ovarian Neoplasms; Solid tumours
詳細
NY-ESO-1 TCR/IL-15 NKPhase 2 ClinicalReplay Holdings LLC, Syena, The University Of Texas MD Anderson Cancer Center
Liposarcoma, Myxoid; Multiple Myeloma; Sarcoma, Synovial
詳細
TC-N201(TCRCure)TC-N201Phase 2 ClinicalTcrcure Biopharma Ltd
Neoplasms; Solid tumours
詳細
HBI-0201-ESO TCRTHBI-0201-ESO TCRTPhase 2 ClinicalHadassah Medical Organization
Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Melanoma; Neoplasm Metastasis; Ovarian Neoplasms; Sarcoma; Sarcoma, Synovial; Triple Negative Breast Neoplasms
詳細
NY-ESO-1 TCR(Kite Pharma)Phase 2 ClinicalKite Pharma, National Cancer Institute
Esophageal Neoplasms; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Melanoma; Meningioma; Neoplasm Metastasis; Ovarian Neoplasms; Peritoneal Neoplasms; Sarcoma; Sarcoma, Synovial; Skin Melanoma; Solid tumours; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
詳細
Letetresgene autoleucelGSK-3377794; GSK-794Phase 2 ClinicalAdaptimmune Llc
Carcinoma, Non-Small-Cell Lung; Melanoma; Multiple Myeloma; Neoplasms; Ovarian Neoplasms
詳細
Anti-NY-ESO-1 murine TCR transduced autologous peripheral blood lymphocytes (Albert Einstein College of Medicine/NCI)Phase 1 ClinicalAlbert Einstein College Of Medicine Inc, National Cancer Institute
Neoplasms
詳細
NeldaleucelMT601; MT-601Phase 1 ClinicalMarker Therapeutics Inc
Hodgkin Disease; Lymphoma, Non-Hodgkin; Pancreatic Neoplasms
詳細
Super 1 T-cell receptor therapy (Guangzhou FineImmune Biotechnology)Phase 1 ClinicalGuangzhou Fineimmune Biotechnology
Lung Neoplasms; Melanoma; Sarcoma; Solid tumours
詳細
PeptiCRAd-1Valo-D102; PeptiCRAd-1Phase 1 ClinicalValor Biotherapeutics
Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liposarcoma, Myxoid; Neoplasms; Osteosarcoma; Sarcoma; Sarcoma, Synovial; Skin Melanoma; Triple Negative Breast Neoplasms
詳細
Autologous T Cells Expressing a High Affinity TCR Specific for NY-ESO-1 (LauT-1) therapy(Centre Hospitalier Universitaire Vaudois)LauT-1Phase 1 ClinicalCentre Hospitalier Universitaire Vaudois
Melanoma; Sarcoma
詳細
DS-2243DS-2243a; DS-2243Phase 1 ClinicalDaiichi Sankyo Co Ltd
Sarcoma; Solid tumours
詳細
SY-104SY-104Phase 1 ClinicalReplay Holdings LLC
Multiple Myeloma; Sarcoma
詳細
MDG-1015MDG1015; MDG-1015Phase 1 ClinicalMedigene Ag
Carcinoma, Ovarian Epithelial; Gastroesophageal Junction Neoplasms; Liposarcoma; Liposarcoma, Myxoid; Ovarian Neoplasms; Sarcoma, Synovial; Soft Tissue Neoplasms; Solid tumours; Stomach Neoplasms
詳細
TCR-T cells(Fujian Province Tumor Hospita)Phase 1 ClinicalFujian Cancer Hospital
Solid tumours
詳細
LYL-132LYL-132; GSK-4427296Phase 1 ClinicalLyell Immunopharma Inc
Neoplasms; Solid tumours
詳細
HLA-A*02:01/NY-ESO-1 TCR-T cell therapy (Pregene)Phase 1 ClinicalShenzhen Pregene Biopharma Co Ltd
Sarcoma
詳細
anti-NY-ESO-1 TCR T-cell therapy (Shenzhen BinDeBio)ClinicalShenzhen Bindebio Ltd
Neoplasms
詳細
NYESOiNTClinicalEutilex
Neoplasms; Ovarian Neoplasms; Sarcoma
詳細